Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression
arXiv Preprint Archive February 4, 2021 Erik D. Fagerholm, Robert Leech, Steven C. R. Williams et al.
The glutamatergic modulator ketamine has been shown to rapidly reduce depressive symptoms in patients with treatment-resistant major depressive disorder (TRD). Although its mechanisms of action are not fully understood, changes in cortical excitation/inhibition (E/I) following ketamine administration are well documented in animal models and could represent a potential biomarker of treatment...